Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

Lee E. Moore, Ruth M. Pfeiffer, Zhen Zhang, Karen H. Lu, Eric T. Fung, Robert C. Bast

Research output: Contribution to journalArticle

Abstract

BACKGROUND: When epithelial ovarian cancer is detected at an early stage (I-II), the 5-year survival rate is between 70% and 90%; whereas, when it is detected in late stages (III-IV), the 5-year survival rate slips to

Original languageEnglish (US)
Pages (from-to)91-100
Number of pages10
JournalCancer
Volume118
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Early Detection of Cancer
Proteomics
Ovarian Neoplasms
Colorectal Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Biomarkers
Serum
Ovarian epithelial cancer

Keywords

  • biomarkers
  • CA 125
  • Colorectal
  • early detection
  • Lung
  • ovarian cancer
  • Ovarian Cancer Screening Trial
  • Prostate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. / Moore, Lee E.; Pfeiffer, Ruth M.; Zhang, Zhen; Lu, Karen H.; Fung, Eric T.; Bast, Robert C.

In: Cancer, Vol. 118, No. 1, 01.01.2012, p. 91-100.

Research output: Contribution to journalArticle

@article{468653584ff04a8f80e9b0f4a0753840,
title = "Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial",
abstract = "BACKGROUND: When epithelial ovarian cancer is detected at an early stage (I-II), the 5-year survival rate is between 70{\%} and 90{\%}; whereas, when it is detected in late stages (III-IV), the 5-year survival rate slips to",
keywords = "biomarkers, CA 125, Colorectal, early detection, Lung, ovarian cancer, Ovarian Cancer Screening Trial, Prostate",
author = "Moore, {Lee E.} and Pfeiffer, {Ruth M.} and Zhen Zhang and Lu, {Karen H.} and Fung, {Eric T.} and Bast, {Robert C.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1002/cncr.26241",
language = "English (US)",
volume = "118",
pages = "91--100",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

AU - Moore, Lee E.

AU - Pfeiffer, Ruth M.

AU - Zhang, Zhen

AU - Lu, Karen H.

AU - Fung, Eric T.

AU - Bast, Robert C.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - BACKGROUND: When epithelial ovarian cancer is detected at an early stage (I-II), the 5-year survival rate is between 70% and 90%; whereas, when it is detected in late stages (III-IV), the 5-year survival rate slips to

AB - BACKGROUND: When epithelial ovarian cancer is detected at an early stage (I-II), the 5-year survival rate is between 70% and 90%; whereas, when it is detected in late stages (III-IV), the 5-year survival rate slips to

KW - biomarkers

KW - CA 125

KW - Colorectal

KW - early detection

KW - Lung

KW - ovarian cancer

KW - Ovarian Cancer Screening Trial

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=83855160925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83855160925&partnerID=8YFLogxK

U2 - 10.1002/cncr.26241

DO - 10.1002/cncr.26241

M3 - Article

C2 - 21717433

AN - SCOPUS:83855160925

VL - 118

SP - 91

EP - 100

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -